In the absence of an approved product, investors’ focus will be on the progress of Zynerba Pharmaceuticals, Inc.’s ZYNE lead pipeline candidate, Zygel, when the company reports third-quarter 2019 results.
The company’s earnings beat the Zacks Consensus Estimate in three of the last four quarters and met the same once with the average positive surprise being 17.07%.
Shares of Zynerba have surged 273.7% so far this year against the industry‘s decline of 4.2%.
In the last reported quarter, Zynerba’s earnings matched estimates.
Things to Watch Out For
Zynerba is focused on developing cannabinoid therapies for rare neuropsychiatric disorders.
A pivotal study — CONNECT-FX — is evaluating Zygel for treating patients with FXS aged 3 to 17 years. Data from the study presented earlier showed improvement in core emotional and behavioral symptoms of statistical significance. Zynerba expects to report top-line data and submit a new drug application next year. Investors will likely have questions regarding any update on the progress of the study on the company’s third-quarter earnings call.
Moreover, Zynerba is also conducting two open-label phase II studies evaluating Zygel for the treatment of autism spectrum disorder and 22q11.2 deletion syndrome.
These ongoing studies are likely to have driven operating expenses higher in the soon-to-be reported quarter.
Key Development
In September, Zynerba announced positive top-line data from the open-label phase II study, BELIEVE 1, which evaluated Zygen in patients with developmental and epileptic encephalopathies (“DEE”). Data from the study showed that the candidate achieved 44% to 58% monthly median reductions in seizures in DEE patients compared to baseline over treatment duration of two to six months.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Zynerba in this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Zynerba’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 51 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Zynerba’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Zynerba Pharmaceuticals, Inc. Price and Consensus
Zynerba Pharmaceuticals, Inc. price-consensus-chart | Zynerba Pharmaceuticals, Inc. Quote
Stocks That Warrant a Look
Here are some stocks from the pharma sector that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Amarin Corporation AMRN has an Earnings ESP of +100.00% and a Zacks Rank #3. The company is scheduled to release third-quarter results on Nov 5. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amicus Therapeutics FOLD has an Earnings ESP of +3.98% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 11.
Eyenovia EYEN has an Earnings ESP of +10.51% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 13.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment